What is the functional role of the thalidomide binding protein cereblon?

International Journal of Biochemistry and Molecular Biology

Volumn 2, Issue 3, 2011, Pages 287-294

  Chang, Xiu Bao ^a   Keith Stewart, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

AMPK; BKCA; CLC 2; CRBN; CUL4A; DDB1; E3 ubiquitin ligase

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; CEREBLON; MEMBRANE PROTEIN; PROTEASOME; THALIDOMIDE; UNCLASSIFIED DRUG;

CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CRBN GENE; ENERGY BALANCE; GENE; GENE FUNCTION; GLYCOLYSIS; HUMAN; HYDROLYSIS; LEARNING; MEMORY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84855928918     PISSN: None     EISSN: 21524114     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Higgins JJ, Rosen DR, Loveless JM, Clyman JC and Grau MJ. A gene for nonsyndromic mental retardation maps to chromosome 3p25-pter. Neurology 2000; 55: 335-340.
2. Higgins JJ, Pucilowska J, Lombardi RQ and Rooney JP. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 2004; 63: 1927-1931.
3. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Ima-mura Y, Yamaguchi Y and Handa H. Identification of a primary target of thalidomide terato-genicity. Science 327: 1345-1350.
4. Dijkhuizen T, van Essen T, van der Vlies P, Ver-heij JB, Sikkema-Raddatz B, van der Veen AY, Gerssen-Schoorl KB, Buys CH and Kok K. FISH and array-CGH analysis of a complex chromosome 3 aberration suggests that loss of CNTN4 and CRBN contributes to mental retardation in 3pter deletions. Am J Med Genet A 2006; 140: 2482-2487.
5. Xin W, Xiaohua N, Peilin C, Xin C, Yaqiong S and Qihan W. Primary function analysis of human mental retardation related gene CRBN. Mol Biol Rep 2008; 35: 251-256.
6. Lee KJ, Lee KM, Jo S, Kang KW and Park CS. Induction of cereblon by NF-E2-related factor 2 in neuroblastoma cells exposed to hypoxia-reoxygenation. Biochem Biophys Res Commun 399: 711-715.
7. Jo S, Lee KH, Song S, Jung YK and Park CS. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J Neurochem 2005; 94: 1212-1224.
8. Higgins JJ, Tal AL, Sun X, Hauck SC, Hao J, Kosofosky BE and Rajadhyaksha AM. Temporal and spatial mouse brain expression of cere-blon, an ionic channel regulator involved in human intelligence. J Neurogenet 24: 18-26.
9. Hohberger B and Enz R. Cereblon is expressed in the retina and binds to voltage-gated chloride channels. FEBS Lett 2009; 583: 633-637.
10. Aizawa M, Abe Y, Ito T, Handa H and Nawa H. mRNA distribution of the thalidomide binding protein cereblon in adult mouse brain. Neurosci Res 69: 343-347.
11. Lee KM, Jo S, Kim H, Lee J and Park CS. Functional modulation of AMP-activated protein kinase by cereblon. Biochim Biophys Acta 1813: 448-455.
12. Narahara K, Kikkawa K, Murakami M, Hiramoto K, Namba H, Tsuji K, Yokoyama Y and Kimoto H. Loss of the 3p25.3 band is critical in the manifestation of del(3p) syndrome: karyotype-phenotype correlation in cases with deficiency of the distal portion of the short arm of chromosome 3. Am J Med Genet A 1990; 35: 269-273.
13. Cargile CB, Goh DL, Goodman BK, Chen XN, Korenberg JR, Semenza GL and Thomas GH. Molecular cytogenetic characterization of a subtle interstitial del(3)(p25.3p26.2) in a patient with deletion 3p syndrome. Am J Med Genet A 2002; 109: 133-138.
14. Knaus HG, Garcia-Calvo M, Kaczorowski GJ and Garcia ML. Subunit composition of the high conductance calcium-activated potassium channel from smooth muscle, a representative of the mSlo and slowpoke family of potassium channels. The Journal of biological chemistry 1994; 269: 3921-3924.
15. Berkefeld H, Fakler B and Schulte U. Ca2+-activated K+ channels: from protein complexes to function. Physiological reviews 2010; 90: 1437-1459.
16. Laumonnier F, Roger S, Guerin P, Molinari F, M'Rad R, Cahard D, Belhadj A, Halayem M, Persico AM, Elia M, Romano V, Holbert S, Andres C, Chaabouni H, Colleaux L, Constant J, Le Guennec JY and Briault S. Association of a functional deficit of the BKCa channel, a synap-tic regulator of neuronal excitability, with autism and mental retardation. The American journal of psychiatry 2006; 163: 1622-1629.
17. Hammond RS, Bond CT, Strassmaier T, Ngo-Anh TJ, Adelman JP, Maylie J and Stackman RW. Small-conductance Ca2+-activated K+ channel type 2 (SK2) modulates hippocampal learning, memory, and synaptic plasticity. The Journal of neuroscience: the official journal of the Society for Neuroscience 2006; 26: 1844-1853.
18. Sausbier M, Hu H, Arntz C, Feil S, Kamm S, Adelsberger H, Sausbier U, Sailer CA, Feil R, Hofmann F, Korth M, Shipston MJ, Knaus HG, Wolfer DP, Pedroarena CM, Storm JF and Ruth P. Cerebellar ataxia and Purkinje cell dysfunction caused by Ca2+-activated K+ channel deficiency. Proceedings of the National Academy of Sciences of the United States of America 2004;101: 9474-9478.
19. Accardi A and Picollo A. CLC channels and transporters: proteins with borderline personalities. Biochimica et biophysica acta 2010; 1798: 1457-1464.
20. Jentsch TJ. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Critical reviews in biochemistry and molecular biology 2008; 43: 3-36.
21. Jentsch TJ. Chloride channels: a molecular perspective. Current opinion in neurobiology 1996; 6: 303-310.
22. Smith RL, Clayton GH, Wilcox CL, Escudero KW and Staley KJ. Differential expression of an inwardly rectifying chloride conductance in rat brain neurons: a potential mechanism for cell-specific modulation of postsynaptic inhibition. The Journal of neuroscience: the official journal of the Society for Neuroscience 1995; 15: 4057-4067.
23. Bosl MR, Stein V, Hubner C, Zdebik AA, Jordt SE, Mukhopadhyay AK, Davidoff MS, Holstein AF and Jentsch TJ. Male germ cells and photo-receptors, both dependent on close cell-cell interactions, degenerate upon ClC-2 Cl(-) channel disruption. The EMBO journal 2001; 20: 1289-1299.
24. Enz R, Ross BJ and Cutting GR. Expression of the voltage-gated chloride channel ClC-2 in rod bipolar cells of the rat retina. The Journal of neuroscience: the official journal of the Society for Neuroscience 1999; 19: 9841-9847.
25. Verhoeven AJ, Woods A, Brennan CH, Hawley SA, Hardie DG, Scott J, Beri RK and Carling D. The AMP-activated protein kinase gene is highly expressed in rat skeletal muscle. Alternative splicing and tissue distribution of the mRNA. European journal of biochemistry/FEBS 1995; 228: 236-243.
26. Adams J, Chen ZP, Van Denderen BJ, Morton CJ, Parker MW, Witters LA, Stapleton D and Kemp BE. Intrasteric control of AMPK via the gamma1 subunit AMP allosteric regulatory site. Protein science: a publication of the Protein Society 2004; 13: 155-165.
27. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D and Hardie DG. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphory-lates AMP-activated protein kinase. The Journal of biological chemistry 1996; 271: 27879-27887.
28. Klip A, Schertzer JD, Bilan PJ, Thong F and An-tonescu C. Regulation of glucose transporter 4 traffic by energy deprivation from mitochondrial compromise. Acta physiologica 2009; 196: 27-35.
29. Cartee GD and Wojtaszewski JF. Role of Akt substrate of 160 kDa in insulin-stimulated and contraction-stimulated glucose transport. Applied physiology, nutrition, and metabolism =Physiologie appliquee, nutrition et metabolisme 2007; 32: 557-566.
30. Santos JM, Ribeiro SB, Gaya AR, Appell HJ and Duarte JA. Skeletal muscle pathways of contraction-enhanced glucose uptake. International journal of sports medicine 2008; 29: 785 -794.
31. Winder WW, Taylor EB and Thomson DM. Role of AMP-activated protein kinase in the molecular adaptation to endurance exercise. Medicine and science in sports and exercise 2006; 38: 1945-1949.
32. Luiken JJ, Coort SL, Koonen DP, Bonen A and Glatz JF. Signalling components involved in contraction-inducible substrate uptake into cardiac myocytes. The Proceedings of the Nutrition Society 2004; 63: 251-258.
33. Krook A, Wallberg-Henriksson H and Zierath JR. Sending the signal: molecular mechanisms regulating glucose uptake. Medicine and science in sports and exercise 2004; 36: 1212-1217.
34. Luiken JJ, Coort SL, Koonen DP, van der Horst DJ, Bonen A, Zorzano A and Glatz JF. Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Archiv: European journal of physiology 2004; 448: 1-15.
35. Richter EA, Derave W and Wojtaszewski JF. Glucose, exercise and insulin: emerging concepts. The Journal of physiology 2001; 535: 313-322.
36. Winder WW. AMP-activated protein kinase: possible target for treatment of type 2 diabetes. Diabetes technology & therapeutics 2000; 2: 441-448.
37. Nag A, Bondar T, Shiv S and Raychaudhuri P. The xeroderma pigmentosum group E gene product DDB2 is a specific target of cullin 4A in mammalian cells. Molecular and cellular biology 2001; 21: 6738-6747.
38. Chen X, Zhang Y, Douglas L and Zhou P. UV-damaged DNA-binding proteins are targets of CUL-4A-mediated ubiquitination and degradation. The Journal of biological chemistry 2001; 276: 48175-48182.
39. Sugasawa K, Okuda Y, Saijo M, Nishi R, Ma-tsuda N, Chu G, Mori T, Iwai S, Tanaka K and Hanaoka F. UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. Cell 2005; 121: 387-400.
40. Groisman R, Kuraoka I, Chevallier O, Gaye N, Magnaldo T, Tanaka K, Kisselev AF, Harel-Bellan A and Nakatani Y. CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome. Genes & development 2006; 20: 1429-1434.
41. Groisman R, Polanowska J, Kuraoka I, Sawada J, Saijo M, Drapkin R, Kisselev AF, Tanaka K and Nakatani Y. The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell 2003; 113: 357-367.
42. Kapetanaki MG, Guerrero-Santoro J, Bisi DC, Hsieh CL, Rapic-Otrin V and Levine AS. The DDB1-CUL4ADDB2 ubiquitin ligase is deficient in xeroderma pigmentosum group E and targets histone H2A at UV-damaged DNA sites. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 2588-2593.
43. Wang H, Zhai L, Xu J, Joo HY, Jackson S, Erd-jument-Bromage H, Tempst P, Xiong Y and Zhang Y. Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Molecular Cell 2006; 22: 383-394.
44. Liu C, Powell KA, Mundt K, Wu L, Carr AM and Caspari T. Cop9/signalosome subunits and Pcu4 regulate ribonucleotide reductase by both checkpoint-dependent and -independent mechanisms. Genes & development 2003; 17: 1130-1140.
45. Higa LA, Mihaylov IS, Banks DP, Zheng J and Zhang H. Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nature cell biology 2003; 5: 1008-1015.
46. Hu J, McCall CM, Ohta T and Xiong Y. Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Nature cell biology 2004; 6: 1003-1009.
47. Bondar T, Ponomarev A and Raychaudhuri P. Ddb1 is required for the proteolysis of the Schizosaccharomyces pombe replication inhibitor Spd1 during S phase and after DNA damage. The Journal of biological chemistry 2004; 279: 9937-9943.
48. Wertz IE, O'Rourke KM, Zhang Z, Dornan D, Arnott D, Deshaies RJ and Dixit VM. Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science 2004; 303: 1371-1374.
49. Liu C, Poitelea M, Watson A, Yoshida SH, Shi-moda C, Holmberg C, Nielsen O and Carr AM. Transactivation of Schizosaccharomyces pombe cdt2+ stimulates a Pcu4-Ddb1-CSN ubiquitin ligase. The EMBO journal 2005; 24: 3940-3951.
50. Angers S, Li T, Yi X, MacCoss MJ, Moon RT and Zheng N. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 2006; 443: 590-593.
51. Zimmerman ES, Schulman BA and Zheng N. Structural assembly of cullin-RING ubiquitin ligase complexes. Current opinion in structural biology 2010; 20: 714-721.
52. Miller MT and Stromland K. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 1999; 60: 306-321.
53. Melchert M and List A. The thalidomide saga.The international journal of biochemistry & cell biology 2007; 39: 1489-1499.
54. Knobloch J and Ruther U. Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle 2008; 7: 1121-1127.
55. Ito T, Ando H and Handa H. Teratogenic effects of thalidomide: molecular mechanisms. Cell Mol Life Sci 68: 1569-1579.
56. van Rhee F, Dhodapkar M, Shaughnessy JD, Jr., Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S and Barlogie B. First thalidomide clinical trial in multiple myeloma: a decade. Blood 2008; 112: 1035-1038.
57. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J and Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. The New England journal of medicine 1999; 341: 1565-1571.
58. Stewart AK. Novel therapies for relapsed myeloma. Hematology Am Soc Hematol Educ Program 2009; 578-586.
59. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ and Prince HM. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2010; 24: 22-32.
60. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ and Stewart AK. Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood 2011;
61. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ and Or-lowski RZ. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 286: 11009-11020.
62. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X and He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837-847.
63. Higgins JJ, Hao J, Kosofsky BE and Rajadhyak-sha AM. Dysregulation of large-conductance Ca2+-activated K+ channel expression in non-syndromal mental retardation due to a cereblon p.R419X mutation. Neurogenetics 2008; 9: 219-223.
64. Jakubikova J, Adamia S, Kost-Alimova M, Klip-pel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC and Mitsiades CS. Lenalidomide targets clonogenic side population in multiple myeloma: patho-physiologic and clinical implications. Blood 2011; 117: 4409-4419.